NORDIC CAPITAL ACQUIRES SPECIALTY PHARMACEUTICAL COMPANY ADVANZ PHARMA IN DEAL WORTH ~$846 MILLION

NORDIC CAPITAL ACQUIRES SPECIALTY PHARMACEUTICAL COMPANY ADVANZ PHARMA IN DEAL WORTH ~$846 MILLION

• The acquisition will bring significant investment and expertise to help fuel ADVANZ PHARMA’s growth, with the potential to bring further cost-savings to the NHS and wider European healthcare systems while enhancing choice and access to critical medicines globally.

LONDON, June 01, 2021 /CNW/ - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, today announced the completion of its acquisition by a subsidiary of Nordic Fund X Epsilon, Cidron Aida Bidco Limited ("Bidco").

Graeme Duncan, Chief Executive Officer of ADVANZ PHARMA, said: "This deal is fantastic news for ADVANZ PHARMA and our goal of becoming the go-to partner for complex medicines in Europe. Nordic Capital will be pivotal in helping the business through both its deep sector expertise and access to capital that will enable considerable investment in our organic and inorganic pipeline. This partnership will be essential in allowing us to further broaden choice for both prescribers and patients throughout the world and ensure access to the essential medicines we supply.

Duncan continues: “This deal could not have been possible without our employees whose hard work has been instrumental in collectively contributing towards building ADVANZ PHARMA into the strong and diverse company it is today.”